Addex ADX71441 Demonstrates Preclinical Analgesic Effects

Home/Lifesci News/Addex ADX71441 Demonstrates Preclinical Analgesic Effects

Addex ADX71441 Demonstrates Preclinical Analgesic Effects

Geneva, Switzerland, 9 May 2017 – Addex Therapeutics (ADXN.SW) announced today positive results from multiple preclinical studies of ADX71441, a positive allosteric modulator (PAM) of the gamma-aminobutyric acid subtype B (GABAB) receptor, in models of visceral hyperalgesia. The studies were led by Prof. Jyoti N. Sengupta at the Medical College of Wisconsin, with the support of a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the US National Institute of Health. The findings strongly support the potential of ADX71441 in treating hyperalgesia in colonic inflammation (colitis) and bladder inflammation (cystitis). Chronic visceral pain syndromes related to the gastrointestinal or urinary tract represent an important unmet medical need as they can significantly impact the patient`s quality of life.

2017-08-07T14:58:13+00:00